Skip to content
Parakho

Natco Pharma Ltd

NSE NATCOPHARMBSE 524816natcopharma.co.inInvestor relations

Q1 FY27, unaudited

Revenue
₹596.60 Cr
Profit after tax
₹74.60 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations596.60−49.98%3,594.60
Other income48.30−18.96%281.10
Total income644.90−48.50%3,875.70
Employee benefit expense151.40+5.51%591.70
Finance costs9.60+269.23%32.30
Depreciation & amortisation42.70−20.63%189.60
Total expenses542.90−23.47%2,511.60
Profit before tax102.00−81.21%1,364.10
Tax expense27.40−65.23%82.60
Profit after tax74.60−83.93%1,281.50
Total comprehensive income85.30−81.77%1,308.30
Earnings per share
Earnings per share, basic₹4.17₹71.55
Earnings per share, diluted₹4.17₹71.55

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

NATCO Pharma reported consolidated revenue of INR794.4 crores for Q1 FY27, down from INR1,390.6 crores a year earlier, mainly due to lower Lenalidomide revenue partly offset by growth in the base business. EBITDA margin was 30.9%, and consolidated PAT was INR206.5 crores, aided by a strong contribution from associate Adcock Ingram driven by a flu season in South Africa. Management discussed a proposed fundraise of INR2,000 crores, an increased 49% stake in Adcock Ingram, and updates on the semaglutide, olaparib, carfilzomib and Crop Health Sciences businesses.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 57 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 07 Oct 2026.